Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.71 |
| ▸ | MEN1 | O00255 | 9/20 | 0.71 |
| ▸ | MAPT | P10636 | 9/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | CASP1 | P29466 | 1/20 | 0.71 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.71 |
| ▸ | CASP7 | P55210 | 1/20 | 0.71 |
| ▸ | HBB | P68871 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 7/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.68 |
| ▸ | CRHBP | P24387 | 2/20 | 0.68 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23009463 | 0.85 | ALDH1A1 (0.67) | LIMK1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL4193459 | 0.84 | LIMK1 (1.00) | LIMK1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL14954964 | 0.84 | LIMK1 (0.84) | LIMK1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL18153568 | 0.84 | HPGD (0.61) | KMT2AKDM4EALDH1A1MEN1MAPT | |
| SCHEMBL12562430 | 0.83 | KMT2A (1.00) | LIMK1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL31748998 | 0.83 | KMT2A (1.00) | LIMK1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL17586006 | 0.78 | MAPT (0.75) | LIMK1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL431962 | 0.78 | KMT2A (0.77) | LIMK1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL18537673 | 0.77 | MAPT (0.88) | LIMK1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL19000365 | 0.77 | MAPT (0.86) | LIMK1KMT2AKDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20160152635-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9301949-B2 | Thienopyridine derivatives for the treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2014089378-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | LIMK1 2427/4885KMT2A 2433/4885KDM4E 1399/4885 |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | LIMK1 2446/4885KMT2A 2603/4885KDM4E 1403/4885 |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | LIMK1 2446/4885KMT2A 2603/4885KDM4E 1403/4885 |
| US-20160152635-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | LIMK1 2427/4885KMT2A 2433/4885KDM4E 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.